Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.41 AUD | -2.38% | +7.79% | +20.29% |
04:04am | Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial | MT |
Apr. 30 | Canaccord Starts Immutep at Buy, Price Target is AU$1.00 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.29% | 324M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Says More Sites Added to Insight-003 Phase 1 Trial for Lung Cancer Treatment